Next Article in Journal
Inflammation and Cell Death in Age-Related Macular Degeneration: An Immunopathological and Ultrastructural Model
Next Article in Special Issue
The Potential for iPS-Derived Stem Cells as a Therapeutic Strategy for Spinal Cord Injury: Opportunities and Challenges
Previous Article in Journal / Special Issue
The Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone Disorders
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2014, 3(4), 1511-1541; doi:10.3390/jcm3041511

iPS Cells for Modelling and Treatment of Retinal Diseases

1
Centre for Ophthalmology and Visual Science (Incorporating Lions Eye Institute), The University of Western Australia, Perth WA 6009, Australia
2
Ophthalmology Department, Royal Perth Hospital, Perth WA 6009, Australia
3
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain
4
School of Medicine and Pharmacology, University of Western Australia, Crawley, Perth WA 6009, Australia
5
Faculty of Medicine, Westmead Children's Hospital, Division of Paediatrics and Child Health, University of Sydney Medical School, Sydney NSW 2145, Australia
6
Developmental and Stem Cell Biology, Victor Chang Cardiac Research Institute, Sydney NSW 2145, Australia
7
Department of Vitreoretinal Surgery, Moorfields Eye Hospital, London EC1V 2PD, UK
8
Division of Cellular Therapy, Institute of Ophthalmology, University College of London, London EC1V 9EL, UK
*
Author to whom correspondence should be addressed.
Received: 22 September 2014 / Revised: 16 November 2014 / Accepted: 18 November 2014 / Published: 19 December 2014
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
View Full-Text   |   Download PDF [2391 KB, uploaded 19 December 2014]   |  

Abstract

For many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has added a powerful alternative tool for discovering new disease-causing mutations, studying genotype-phenotype relationships, performing therapeutics-toxicity screening and developing personalised cell therapy. This review article provides a clinical perspective on the current and potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited retinal diseases and age-related macular degeneration. View Full-Text
Keywords: age-related macular degeneration; inherited retinal disease; retinal dystrophy; macular dystrophy; retina; induced pluripotent; stem cells; cell transplantation; disease modelling; genetic diagnosis age-related macular degeneration; inherited retinal disease; retinal dystrophy; macular dystrophy; retina; induced pluripotent; stem cells; cell transplantation; disease modelling; genetic diagnosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chen, F.K.; McLenachan, S.; Edel, M.; Da Cruz, L.; Coffey, P.J.; Mackey, D.A. iPS Cells for Modelling and Treatment of Retinal Diseases. J. Clin. Med. 2014, 3, 1511-1541.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top